UBS Group’s Abivax ABVX Stock Holding History
Bought
Maintained
Sold
Other funds holding ABVX
DGM
UBS Group's ABVX Position: Q3 2026 in Review
UBS Group reduced its Abivax (ABVX) stake by 79% in Q3 2026, selling an estimated $177M and leaving 380,365 shares worth $37.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1980.
UBS Group first reported a position in ABVX in Q1 2024 and has held it in 10 quarters since. The position peaked at $597M in Q4 2025. 319 funds tracked by Wall St. Rank hold ABVX as of Q3 2026.
- UBS Group held 380,365 shares of Abivax worth $37.7M as of Q3 2026.
- UBS Group sold 1,464,553 Abivax shares in Q3 2026, an estimated $177M.
- Abivax made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #1980 holding.
- UBS Group first reported a position in Abivax in Q1 2024 and has held it in 10 quarters since.
- UBS Group's Abivax position peaked at $597M in Q4 2025.
- 319 funds tracked by Wall St. Rank held Abivax as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.